• Age range from 18 to 75 years;

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

• Pathologically confirmed relapsed/refractory Peripheral T-cell lymphoma (Including PTCL-NOS, AITL, anaplastic large cell lymphoma（ALTL）, excluding Nature Killer（NK）/T cell lymphoma);

• At least one two-dimensional measurable lesion with a length diameter of at least 1.5cm and vertical diameter of at least 1.0cm (measured by CT or MRI);

• Adequate medullary hematopoiesis function ( WBC≥3.5×109/L, ANC≥1.5×109/L, PLT≥80×109/L, HB≥90g/L. If the peripheral blood indicators demonstrate abnormal due to bone marrow or spleen invasion by lymphoma, Enrollment decision can be determined by the investigator as appropriate;

• Adequate hepatic function (total serum bilirubin, ALT and AST≤1.5 times of upper limit of normal);

• Adequate renal function (serum creatinine≤1.5 times the upper limit of normal, creatinine clearence≥50ml/min);

• Echocardiography or radionuclide cardia functional test, LVEF≥50%;

• Patients of child-bearing period agree to use appropriate contraception. The serum pregnancy test of women in childbearing period was negative within 2 weeks before enrollment.

⁃ Willingness to provide pathological tissue specimens (20 pieces of wax or paraffin tissue sections);

⁃ Expectation survival time over 3 months;

⁃ Willingness to provide written informed consent.